Treatment Information

Back

Prostate Cancer treatment details. Hormone.

University of California San Francisco, San Francisco, California, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:San Francisco, California
Treatments:HormoneHospital:University of California San Francisco
Drugs:Journal:Link
Date:Sep 2004

Description:

Patients: This Phase III trial involved a total of 260 patients with hormone refractory (androgen independent) prostate cancer. Patients were divided into two groups: Group 1 with 132 patients and Group 2 with 128 patients. The median age for patients in Group 1 was 71 years. For both groups, the median PSA was 58 years.

Treatment: Patients in Group 1 underwent anti-androgen withdrawal only.

Toxicity: For patients in Group 1 the only grade 3-4 toxicity was hepatic (presumably attributed to causes other than the anti-androgen withdrawal itself).

Results: For patients in Group 1 the median survival was 16.7 months.

Support: Support was provided by Janssen Pharmaceutica Products. This company markets ketoconazole under the brand name nizoral.

Correspondence: Eric J. Small, MD




Back